Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo’s nucleoside analog 3TC

Executive Summary

Is in two Phase II/III trials in North America involving a total of 645 AIDS patients. One trial involves a comparison of three treatment groups: low dose 3TC with AZT (Burroughs Wellcome's Retrovir) versus high dose 3TC with AZT versus ddC (Roche's Hivid) with AZT in treating HIV-infected, AZT-experienced ( >/= 24 weeks) patients with CD4 cell counts of 100-300/mm. The other study involves a comparison of four arms: 3TC alone, AZT alone, low dose 3TC with AZT and high dose 3TC with AZT in HIV- infected patients, who are AZT naive ( </= 4 weeks) with CD4 cell counts of 200-500/mm. "The Pink Sheet" (Nov. 8, T&G-5) incorrectly described the total number of patients and design of the protocols.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel